Regenxbio Inc (RGNX) Q4 2024 Earnings Call Highlights: Strategic Advances and Financial Resilience
Regenxbio Inc (RGNX) showcases robust financial positioning and strategic progress in gene therapy, despite challenges in ...
HC Wainwright Has Bullish Forecast for REGENXBIO Q1 Earnings
Analysts at HC Wainwright increased their Q1 2025 earnings estimates for shares of REGENXBIO in a note issued to investors on ...
Sarepta safety update on Elevidys boosts Regenxbio, hurts Solid Bio
Regenxbio (RGNX) stock gains and Solid Biosciences (SLDB) stock falls after Sarepta Therapeutics' (SRPT) safety update on ...
Barclays Keeps Their Buy Rating on RegenXBio (RGNX)
Barclays analyst Gena Wang maintained a Buy rating on RegenXBio (RGNX – Research Report) yesterday and set a price target of $50.00. The ...
The Pharma Letter17h
Regenxbio’s RGX-202 continues to show promise in DMD
US gene therapy company Regenxbio has reported new, positive interim data from two additional patients in the Phase I/II ...
REGENXBIO Inc. (NASDAQ:RGNX) Is About To Turn The Corner
We feel now is a pretty good time to analyse REGENXBIO Inc.'s ( NASDAQ:RGNX ) business as it appears the company may ...
HC Wainwright Issues Pessimistic Forecast for REGENXBIO (NASDAQ:RGNX) Stock Price
REGENXBIO (NASDAQ:RGNX – Free Report) had its price target cut by HC Wainwright from $36.00 to $34.00 in a research report ...
RBC Capital Sticks to Its Buy Rating for RegenXBio (RGNX)
In a report released on March 14, Luca Issi from RBC Capital maintained a Buy rating on RegenXBio (RGNX – Research Report), with a price target ...
REGENXBIO Inc. (NASDAQ:RGNX) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Call Transcript March 13, 2025 REGENXBIO Inc. beats earnings expectations. Reported EPS is $-1.01, ...
Stifel Nicolaus Keeps Their Buy Rating on RegenXBio (RGNX)
Stifel Nicolaus analyst Annabel Samimy maintained a Buy rating on RegenXBio (RGNX – Research Report) today and set a price target of $40.00. The company’s shares closed yester ...